Background: Detection of antiphospholipid antibodies (aPL) can be considered problematic due to assay variability and reagent sensitivity, high false-positive and false-negative rates, and lack of assay standardization. Therefore, utilizing an automated system can improve reproducibility and reduce interlaboratory variation. Here, we evaluated the analytical performance of the new automated ACL AcuStar chemiluminescence assay (Instrumentation Laboratory, USA). This was compared to the results of a panel analyzed with the QUANTA Lite ELISA (INOVA Diagnostics Inc., USA). Methods: We evaluated the inter-assay precision, linearity, and carry-over between the two methods, ACL and ELISA. A reference range study for each of the anticardiolipin (aCL) and anti-b 2 glycoprotein-I (ab 2 GPI) IgG and IgM antibodies were performed using 135 healthy patient samples, which served as controls. We then compared the accuracy among the AcuStar and ELISA systems via four aPL tests. For this comparison, 69 patient samples suspected of an autoimmune disorder were used as the experimental panel.
INTRODUCTION
Antiphospholipid syndrome (APS) is an autoimmune condition characterized by arterial or venous thrombosis and/or pregnancy complications due to the persistent presence of antiphospholipid antibodies (aPL). These aPL are naturally occurring heterogeneous autoantibodies that bind to phospholipid-bound proteins [1] [2] [3] . aPL associated with APS includes lupus anticoagulant (LA), anticardiolipin (aCL), and anti-b 2 glycoprotein-I (ab 2 GPI) IgG or IgM antibodies.
To make a conclusive diagnosis of APS, at least one of the clinical and laboratory criteria need to be met [4, 5] .
Laboratory abnormality must be present on two or more occasions and at least 12 weeks apart. Systematic reviews have reported that LA is a stronger risk factor for both thrombosis and obstetric complications compared to aCL or ab 2 GPI antibodies [1] [2] [3] [4] [5] . However, three aPL have now been associated with the highest risk for thrombosis and so can be implemented in laboratory criteria for APS [1] [2] [3] [4] [5] . Thus, evaluation of patients using aPL profile rather than a separate test may be more useful in assessing thrombotic risk.
The laboratory identification of aPL can be problematic because the available tests have sensitivity and specificity variability, poor reproducibility, and a lack of standardization [6] [7] [8] [9] . Currently, aCL and ab 2 
Evaluation of Analytical Performance Evaluation
Inter-assay precision was assessed using the low and high control materials according to the Clinical and Laboratory Standards Institute (EP05-A2) [13] . Each control was analyzed in duplicate for 5 days with two runs a day. Linearity study of dilution recovery was performed using clinical samples according to CLSI EP06-A [14] .
Two serum samples with concentrations within ±10%
of the upper limit of analytical measurement range (AMR) and within ±50% of the lower limit of AMR were proportionately mixed and tested in duplicates. We also evaluated percent carry-over using one normal and one high abnormal sample. A reference range study, for each of AcuStar aPL tests, was performed using 135 healthy control samples according to CLSI EP28-A3c [15] . The cutoff values of our laboratory were assigned at the 99th percentile. We compared the results for aCL and ab 2 GPI 
RESULTS

Precision, Linearity, and Carry-Over
The AcuStar aPL assay panel was evaluated for several analytical performance characteristics including precision, linearity, and carry-over. Table 1 shows within run and total % CV at low and high concentration levels. AcuStar assays demonstrated within run and total CV of ＜7.0%
and ＜9.0%, respectively. The AcuStar analyzer showed excellent linearity for all four assays evaluated, within the allowable systemic errors of 10.0% (1.7% to 4.5%). The AMR specified by the manufacturer was 2.6-2,024 U/mL for aCL IgG, 1.0-774 U/mL for aCL IgM, 6.4-6,100 U/mL for ab 2 GPI IgG, and 1.1-841 U/mL for ab 2 GPI IgM, while reportable ranges validated in this study were 2.6-40,480 U/mL, 1.0-15,480 U/mL, 6.4-122,000 U/mL, and 1.1-16,820 U/mL, respectively. The carry-over was also all within ±1.0% (-0.8% to 0.2%).
Reference Ranges
The upper reference limits were calculated within the 4 AcuStar alone positive) tests, respectively. Table 2 shows the analytical agreement of the AcuStar aPL assay However, the analytical agreement and kappa statistics were comparable between the two different cutoffs.
We also compared the numerical test results between AcuStar and ELISA using a Pearson correlation coefficient. In Fig. 1 , all assays showed significant correlation determined by correlation coefficient r values (P＜0.0001). Between AcuStar and ELISA, both aCL and ab 2 GPI showed better correlation for IgG than for IgM.
DISCUSSION
APS is a heterogeneous autoimmune disorder characterized by a wide range of clinical features, primarily thrombotic or obstetric complications. These clinical manifestations lack specificity. Therefore, a defining feature of APS is persistent aPL, being able to identify The laboratory detection of aPL can be problematic due to poor assay reproducibility and the lack of standardization. In relation to these issues, guidelines for laboratory identification of aPL have been published and updated by international working groups [4] [5] [6] 8] .
Recommendations covering the contributing factors include standards, calibration, and assay-specific. Application of these guidelines can help in implementing the best practices and the standardization of the assays.
Besides conventional ELISA, new platforms and detection technologies have been introduced [10] [11] [12] [18] [19] [20] [21] [22] .
The new automated platforms are expected to improve reproducibility and reduce interlaboratory variation.
AcuStar assays demonstrated within run and total CV of ＜7.0% and ＜9.0%, respectively. Precision is an important requirement, especially for automated analyzers;
therefore, a between run imprecision of ＜10% is recommended [5, 6, 8, 9, 17] . ELISAs [11] .
According to the guidelines, it is recommended that laboratories determine their own in-house cutoff values by the 99th percentile of a healthy population of at least 120 healthy patient samples. In our study, calculated cutoffs were close to those of the manufacturer and only differed for ab 2 GPI IgM (11.9 U/mL versus 20 U/mL, respectively In conclusion, these data suggest that the new AcuStar chemiluminescence assay shows good performance features. The automation can improve the reproducibility allowing for reduction in interlaboratory variation. We are now planning future studies to determine the clinical significance of aPL.
